The new device is designed to treat a variety of indications with faster results and minimal downtime.
The industry-leading medical device provider, Lumenis has launched a new CO₂ laser, called ULTRApulse Alpha, to the UK market.
According to the company, the innovation was propelled by market growth and patient demand for effective, non-invasive solutions with minimal downtime.
Benefitting from Lumenis’ proven experience and track record as the first company to introduce the CO₂ laser to aesthetics, ULTRApulse® Alpha combines the best of CO₂ laser technology with an advanced and easy-to-use platform, allowing aesthetic providers to treat a variety of indications.
The technology comes complete with a contemporary and intuitive Graphical User Interface (GUI), hosting presets and intelligent automations, for treatments ranging from skin resurfacing and scar revision, to even minimally invasive aesthetic surgeries like Blepharoplasty.
The device offers versatility and precision for all your resurfacing needs due to multiple fractional modes. TotalFX, for example, combines superficial and deep treatments in a single session, improving results without increasing downtime. In SCAARFX mode, the laser can reach up to 4mm in a single pulse, which is ideal for treating deep, thick lesions, while having the shortest possible pulse duration – faster than the tissue relaxation time – to minimise thermal damage and discomfort.
These modes are offered alongside CoolScan technology for enhanced patient comfort, and the new BrushFX proprietary scanning feature to further reduce potential treatment demarcations.
Moreover, while many other laser skin treatments require recurring visits to achieve noticeable results, ULTRApulse Alpha is said to show results after just one treatment, while maintaining patient safety. The company revealed these results are supported by dozens of clinical studies and peer-reviewed publications too.
“The ULTRApulse Alpha is the embodiment of excellence in CO₂ laser technology that guarantees to make a difference to both patient and practitioner alike,” explained Lumenis’ UK country manager Andrew Greenwell. “With the latest state-of-the-art technology from the original innovators of laser, combined with simplicity of use in its design, ULTRApulse Alpha promises to deliver excellence in safety, results and return on investment. UlLTRApulse Alpha provides the next step in growing your practice and the Lumenis UK team is looking forward to the difference that this device will make to our existing and potential UK partners.“
The ULTRApulse Alpha is already gaining favourable reviews across the world too: “After comparing all fractional-ablative devices, it turns out that the short pulse delivered by ULTRApulse Alpha creates a deep-clean wound, while other devices are less powerful and might deliver more complications,” revealed the medical director and owner of Miami Dermatology and Laser Institute in Miami, Florida, CDr Jill S. Waibel. “Lumenis does such a great job, and the new ULTRApulse Alpha is an amazing device that has upped the game with many new features,” Waibel revealed.
Lumenis is a global leader in the field of energy-based medical solutions for aesthetic and vision applications, with a portfolio that also includes Stellar22 and NuEra Tight. For more information about the capacity of ULTRApulse Alpha, visit information.lumenis.com/ultra-pulse-alpha-uk
